SUNPHARMA Q2 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
Sun Pharma reported Q2 FY27 revenue of INR161,000 million, up 11.8% YoY, with gross margin at 80.8% (higher YoY on better mix and favorable currency). EBITDA grew 4.8% to INR47,439 million but margins declined YoY to 29.3% due to lenalidomide benefit in base quarter. Adjusted PAT was INR31,620 million (reported PAT INR19,885 million after exceptional items). India business grew 17.3% with market share gain to 8.6%; US declined 8.2% YoY on lenalidomide erosion but grew 6.5% QoQ. Emerging Markets grew 7.6%. Innovative Medicines up 6.9% to USD356 million but Ilumya US slowed. R&D at 4.8% of sales, expected to ramp to 6-7% full-year. Organon acquisition on track for Q4 FY27 close. FY27 guidance maintained at high single-digit growth. Key concerns: Ilumya US recovery timeline unclear, no guidance upgrade despite strong H1, acquisition costs and financing details still emerging.
Management Tone
- Prepared Remarks: Good — Management reported 11.8% revenue growth, 80.8% gross margin expansion on better product mix and favorable currency, and strong India business growth of 17.3% with market share gain to 8.6%. R&D spend tracking lower but expected to catch up.
- Q&A Session: Neutral — Analysts pressed on Ilumya US slowdown with management citing 'market and execution' issues without full quantification; no upgrade to FY27 high-single-digit guidance despite H1 double-digit growth; R&D spend guidance reiterated but timing uncertain; Organon borrowing costs and goodwill details defe
Revenue Growth Drivers
- India business volume expansion and new product launches
- Emerging Markets product launches including Ilumya and semaglutide
- US generic product launches (5 new products)
Growth vs Margin Focus
Management emphasizes revenue growth with high single-digit FY27 guidance while investing in R&D pipeline (6-7% of sales) and Organon integration. Margin focus evident in gross margin improvement (80.8%) through better product mix and cost management. However, near-term margins impacted by one-offs
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited (SUNPHARMA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.